+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antinematode Drugs Market - Global Forecast 2026-2032- Product Image
Antinematode Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Antinematode Drugs Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6147125
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antinematode Drugs Market is projected to reach USD 2.66 Billion in 2026. It is expected to continue growing at a CAGR of 5.24%, reaching USD 3.66 Billion by 2032.

Antinematode Drugs: Executive Summary and Market Context

Antinematode drugs are pharmaceutical treatments used to control or eliminate nematode infections in humans and animals. Their role spans clinical care, veterinary medicine, and public-health programs, particularly where soil-transmitted helminths, filarial infections, or livestock parasitism create persistent health and productivity burdens. Demand is shaped by disease prevalence, diagnostic access, treatment guidelines, medicine quality, resistance patterns, and the ability of health systems to reach underserved populations.

Public-Health Integration Is Reshaping Antinematode Drug Use

The landscape is shifting from isolated treatment toward integrated parasite-control programs combining preventive chemotherapy, sanitation, clean water, surveillance, diagnostics, and health education. Regulatory scrutiny increasingly emphasizes safety, pediatric suitability, quality assurance, and responsible use. In veterinary settings, resistance management is encouraging rotation of drug classes, targeted treatment, fecal testing, and improved husbandry rather than routine blanket dosing. These changes favor therapies that can be deployed reliably across community, hospital, pharmacy, and farm settings.

Artificial Intelligence Strengthens Diagnosis, Surveillance, and Stewardship

Artificial intelligence can support antinematode-drug programs by improving image-based parasite detection, triaging clinical records, identifying treatment patterns, and integrating epidemiological, environmental, and laboratory data. Predictive tools may help prioritize screening and monitor signals associated with reduced drug sensitivity. However, useful deployment depends on representative datasets, transparent validation, cybersecurity, clinician oversight, and safeguards against unequal performance across populations. AI should complement, not replace, laboratory confirmation and public-health judgment.

Regional Insights: Uneven Burden and Delivery Capacity Shape Adoption

North America combines established clinical infrastructure with continued veterinary demand and attention to antimicrobial and antiparasitic stewardship. Latin America faces persistent parasitic-disease challenges alongside uneven diagnostic and sanitation access. Europe emphasizes regulatory quality, surveillance, and prudent use in human and animal health. The Middle East requires approaches adapted to migration, climate variability, and healthcare-access differences. Africa remains central to global control efforts because of endemic helminth disease and the importance of mass drug administration. Asia-Pacific presents wide variation, from advanced health systems to high-burden rural settings, making local epidemiology, supply reliability, and community delivery especially important.

Group Insights: Cooperation Supports Access and Stewardship

ASEAN countries benefit from regional coordination while addressing substantial variation in health infrastructure, disease ecology, and medicine access. BRICS members encompass major pharmaceutical, agricultural, and public-health systems, creating opportunities for collaboration on manufacturing, surveillance, and research while requiring strong quality controls. The European Union supports harmonized regulatory and pharmacovigilance practices. G7 members contribute research, financing, and standards-setting capacity. GCC states can coordinate procurement and clinical guidance across closely connected health systems. NATO members must also consider military and humanitarian health preparedness, including supply continuity and parasite control in deployed or displaced populations.

Country Insights: National Priorities Reflect Distinct Disease and System Profiles

Australia emphasizes veterinary parasite management, rural access, and resistance surveillance. Brazil and Mexico balance endemic disease control with large and diverse healthcare systems. Canada and the United States focus on clinical management, travel-related infections, veterinary use, and product oversight. China and India address substantial population diversity, rural delivery needs, and domestic production capabilities. Japan and South Korea bring advanced diagnostics and regulated care pathways. France, Germany, Italy, Spain, and the United Kingdom prioritize evidence-based treatment, pharmacovigilance, and veterinary stewardship within mature regulatory environments. Russia’s priorities include regional access, veterinary health, and supply resilience. Across these countries, effective use depends on reliable diagnosis, appropriate dosing, quality-assured products, and resistance monitoring.

Action Priorities for Leaders in Antinematode Drug Development and Delivery

Industry leaders should align product design with real-world delivery conditions, including pediatric formulations, simplified dosing, temperature stability, and packaging that supports adherence. They should invest in resistance surveillance, diagnostic partnerships, post-treatment monitoring, and responsible-use education for clinicians, pharmacists, veterinarians, and farmers. Access strategies should incorporate transparent procurement, local regulatory requirements, supply-chain redundancy, and collaboration with public-health agencies. AI initiatives should be evidence-based and governed by privacy, validation, and human-oversight standards. Differentiation is strongest when clinical value, operational usability, medicine quality, and stewardship are addressed together.

Research Methodology for a Reliable Antinematode Drug Assessment

A rigorous assessment should combine peer-reviewed clinical and epidemiological literature, national and international health guidance, regulatory documents, pharmacovigilance records, resistance studies, procurement and supply-chain evidence, and veterinary-health sources. Findings should be triangulated across human and animal applications and stratified by geography, pathogen, care setting, age group, and delivery model. Qualitative expert review can clarify implementation barriers, while documented inclusion criteria, source dating, uncertainty assessment, and conflict-of-interest checks support reproducibility. No conclusion should rely on unverified claims or unsupported numerical assumptions.

Conclusion: Effective Control Depends on Integrated, Responsible Use

Antinematode drugs remain important tools for managing parasitic disease, but their impact depends on more than pharmacological activity. Sustainable outcomes require diagnosis, access, adherence, sanitation, surveillance, quality assurance, and resistance stewardship to operate together. Regional and national conditions differ substantially, so implementation should be locally informed while guided by consistent evidence standards. Leaders that combine practical product design, responsible deployment, and carefully governed digital innovation will be better positioned to support durable health outcomes.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Antinematode Drugs Market, by Drug Class
7.1. Introduction
7.2. Avermectins
7.2.1. Ivermectin
7.2.2. Moxidectin
7.3. Benzimidazoles
7.3.1. Albendazole
7.3.2. Febantel
7.3.3. Mebendazole
7.3.4. Thiabendazole
7.4. Nitrothiazoles
7.5. Pyrantel
8. Antinematode Drugs Market, by Dosage Form
8.1. Introduction
8.2. Capsule
8.3. Powder For Suspension
8.4. Suspension
8.5. Tablet
9. Antinematode Drugs Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Topical
10. Antinematode Drugs Market, by Therapeutic Indication
10.1. Introduction
10.2. Filariasis
10.2.1. Lymphatic Filariasis
10.2.2. Onchocerciasis
10.3. Gastrointestinal Nematode Infections
10.3.1. Ascariasis
10.3.2. Hookworm Infection
10.3.3. Strongyloidiasis
10.3.4. Trichuriasis
11. Antinematode Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Over The Counter
11.3. Prescription
12. Antinematode Drugs Market, by End User
12.1. Introduction
12.2. Clinic
12.3. Hospital
12.4. Online Pharmacy
12.5. Retail Pharmacy
13. Antinematode Drugs Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Antinematode Drugs Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Antinematode Drugs Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Anhui Shengying Pharmaceutical Co., Ltd.
17.2. Bayer AG
17.3. Beijing Taiyang Pharmaceutical Co., Ltd.
17.4. Boehringer Ingelheim International GmbH
17.5. Elanco Animal Health Incorporated
17.6. Geevet Remedies Pvt Ltd
17.7. GlaxoSmithKline plc
17.8. Guilin Nanyao Pharmaceutical Co., Ltd.
17.9. Hubei Ruihua Pharmaceutical Co., Ltd.
17.10. Imperia Lifesciences Pvt Ltd
17.11. Jiaozuo Furuitang Pharmaceutical Co., Ltd.
17.12. Jinhe Biotechnology Co., Ltd.
17.13. Johnson & Johnson Services, Inc.
17.14. Merck & Co., Inc.
17.15. Novartis AG
17.16. Pfizer Inc.
17.17. Sanofi S.A.
17.18. Shaanxi Hanwang Pharmaceutical Co., Ltd.
17.19. Shandong Luxi Veterinary Pharmaceutical Co., Ltd.
17.20. Shanghai SPH Xinyi Pharmaceutical Co., Ltd.
17.21. Shanghai Tengrui Pharmaceutical Co., Ltd.
17.22. Shaoxing Minsheng Pharmaceutical Co., Ltd.
17.23. Shijiazhuang Shimu Pharmaceutical Co., Ltd.
17.24. Sichuan Hengtong Animal Protection Biotechnology Co., Ltd.
17.25. Sichuan Tiande Pharmaceutical Co., Ltd.
17.26. Zhejiang Anbet Pharmaceutical Co., Ltd.
17.27. Zhengzhou Yuxiang Agricultural Science and Technology Co., Ltd.
17.28. Zoetis Inc.
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Antinematode Drugs Market, Years Considered for the Study
FIGURE 2. Global Antinematode Drugs Market, Research Design
FIGURE 3. Global Antinematode Drugs Market, Research Framework
FIGURE 4. Global Antinematode Drugs Market, Data Triangulation
FIGURE 5. Global Antinematode Drugs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Antinematode Drugs Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 7. Global Antinematode Drugs Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Antinematode Drugs Market Size, by Dosage Form, 2025 vs 2032 (%)
FIGURE 9. Global Antinematode Drugs Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Antinematode Drugs Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global Antinematode Drugs Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Antinematode Drugs Market Size, by Therapeutic Indication, 2025 vs 2032 (%)
FIGURE 13. Global Antinematode Drugs Market Size, by Therapeutic Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Antinematode Drugs Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Antinematode Drugs Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Antinematode Drugs Market Size, by End User, 2025 vs 2032 (%)
FIGURE 17. Global Antinematode Drugs Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Antinematode Drugs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Antinematode Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Antinematode Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Antinematode Drugs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Antinematode Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Antinematode Drugs Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Antinematode Drugs Market Segmentation & Coverage
TABLE 2. Global Antinematode Drugs Market Size, 2017-2032 (USD Million)
TABLE 3. Global Antinematode Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 4. Global Avermectins Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Avermectins Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Avermectins Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Ivermectin Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Ivermectin Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Ivermectin Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Moxidectin Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Moxidectin Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Moxidectin Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Benzimidazoles Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Benzimidazoles Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Benzimidazoles Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Albendazole Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Albendazole Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Albendazole Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Febantel Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Febantel Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Febantel Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Mebendazole Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Mebendazole Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Mebendazole Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Thiabendazole Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Thiabendazole Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Thiabendazole Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Nitrothiazoles Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Nitrothiazoles Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Nitrothiazoles Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Pyrantel Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Pyrantel Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Pyrantel Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Antinematode Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 35. Global Capsule Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Capsule Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Capsule Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Powder For Suspension Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Powder For Suspension Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Powder For Suspension Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Suspension Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Suspension Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Suspension Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Tablet Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Tablet Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Tablet Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Antinematode Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 48. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Topical Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Topical Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Topical Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Antinematode Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 58. Global Filariasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Filariasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Filariasis Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Lymphatic Filariasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Lymphatic Filariasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Lymphatic Filariasis Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Onchocerciasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Onchocerciasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Onchocerciasis Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Gastrointestinal Nematode Infections Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Gastrointestinal Nematode Infections Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Gastrointestinal Nematode Infections Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Ascariasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Ascariasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Ascariasis Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Hookworm Infection Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Hookworm Infection Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Hookworm Infection Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Strongyloidiasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Strongyloidiasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Strongyloidiasis Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Trichuriasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global Trichuriasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global Trichuriasis Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global Antinematode Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 83. Global Over The Counter Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Global Over The Counter Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. Global Over The Counter Market Size, by Country, 2017-2032 (USD Million)
TABLE 86. Global Prescription Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Global Prescription Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. Global Prescription Market Size, by Country, 2017-2032 (USD Million)
TABLE 89. Global Antinematode Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 90. Global Clinic Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Global Clinic Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. Global Clinic Market Size, by Country, 2017-2032 (USD Million)
TABLE 93. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 96. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 99. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 101. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 102. Global Antinematode Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. Asia-Pacific Antinematode Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Asia-Pacific Antinematode Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 105. Asia-Pacific Antinematode Drugs Market Size, by Avermectins, 2017-2032 (USD Million)
TABLE 106. Asia-Pacific Antinematode Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 107. Asia-Pacific Antinematode Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 108. Asia-Pacific Antinematode Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 109. Asia-Pacific Antinematode Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 110. Asia-Pacific Antinematode Drugs Market Size, by Filariasis, 2017-2032 (USD Million)
TABLE 111. Asia-Pacific Antinematode Drugs Market Size, by Gastrointestinal Nematode Infections, 2017-2032 (USD Million)
TABLE 112. Asia-Pacific Antinematode Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 113. Asia-Pacific Antinematode Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 114. North America Antinematode Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 115. North America Antinematode Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 116. North America Antinematode Drugs Market Size, by Avermectins, 2017-2032 (USD Million)
TABLE 117. North America Antinematode Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 118. North America Antinematode Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 119. North America Antinematode Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 120. North America Antinematode Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 121. North America Antinematode Drugs Market Size, by Filariasis, 2017-2032 (USD Million)
TABLE 122. North America Antinematode Drugs Market Size, by Gastrointestinal Nematode Infections, 2017-2032 (USD Million)
TABLE 123. North America Antinematode Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 124. North America Antinematode Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 125. Latin America Antinematode Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 126. Latin America Antinematode Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 127. Latin America Antinematode Drugs Market Size, by Avermectins, 2017-2032 (USD Million)
TABLE 128. Latin America Antinematode Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 129. Latin America Antinematode Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 130. Latin America Antinematode Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 131. Latin America Antinematode Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 132. Latin America Antinematode Drugs Market Size, by Filariasis, 2017-2032 (USD Million)
TABLE 133. Latin America Antinematode Drugs Market Size, by Gastrointestinal Nematode Infections, 2017-2032 (USD Million)
TABLE 134. Latin America Antinematode Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 135. Latin America Antinematode Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 136. Europe Antinematode Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 137. Europe Antinematode Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 138. Europe Antinematode Drugs Market Size, by Avermectins, 2017-2032 (USD Million)
TABLE 139. Europe Antinematode Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 140. Europe Antinematode Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 141. Europe Antinematode Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 142. Europe Antinematode Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 143. Europe Antinematode Drugs Market Size, by Filariasis, 2017-2032 (USD Million)
TABLE 144. Europe Antinematode Drugs Market Size, by Gastrointestinal Nematode Infections, 2017-2032 (USD Million)
TABLE 145. Europe Antinematode Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 146. Europe Antinematode Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 147. Middle East Antinematode Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 148. Middle East Antinematode Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 149. Middle East Antinematode Drugs Market Size, by Avermectins, 2017-2032 (USD Million)
TABLE 150. Middle East Antinematode Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 151. Middle East Antinematode Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 152. Middle East Antinematode Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 153. Middle East Antinematode Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 154. Middle East Antinematode Drugs Market Size, by Filariasis, 2017-2032 (USD Million)
TABLE 155. Middle East Antinematode Drugs Market Size, by Gastrointestinal Nematode Infections, 2017-2032 (USD Million)
TABLE 156. Middle East Antinematode Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 157. Middle East Antinematode Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 158. Africa Antinematode Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 159. Africa Antinematode Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 160. Africa Antinematode Drugs Market Size, by Avermectins, 2017-2032 (USD Million)
TABLE 161. Africa Antinematode Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 162. Africa Antinematode Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 163. Africa Antinematode Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 164. Africa Antinematode Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 165. Africa Antinematode Drugs Market Size, by Filariasis, 2017-2032 (USD Million)
TABLE 166. Africa Antinematode Drugs Market Size, by Gastrointestinal Nematode Infections, 2017-2032 (USD Million)
TABLE 167. Africa Antinematode Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 168. Africa Antinematode Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 169. Global Antinematode Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 170. ASEAN Antinematode Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 171. ASEAN Antinematode Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 172. ASEAN Antinematode Drugs Market Size, by Avermectins, 2017-2032 (USD Million)
TABLE 173. ASEAN Antinematode Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 174. ASEAN Antinematode Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 175. ASEAN Antinematode Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 176. ASEAN Antinematode Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 177. ASEAN Antinematode Drugs Market Size, by Filariasis, 2017-2032 (USD Million)
TABLE 178. ASEAN Antinematode Drugs Market Size, by Gastrointestinal Nematode Infections, 2017-2032 (USD Million)
TABLE 179. ASEAN Antinematode Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 180. ASEAN Antinematode Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 181. GCC Antinematode Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 182. GCC Antinematode Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 183. GCC Antinematode Drugs Market Size, by Avermectins, 2017-2032 (USD Million)
TABLE 184. GCC Antinematode Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 185. GCC Antinematode Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 186. GCC Antinematode Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 187. GCC Antinematode Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 188. GCC Antinematode Drugs Market Size, by Filariasis, 2017-2032 (USD Million)
TABLE 189. GCC Antinematode Drugs Market Size, by Gastrointestinal Nematode Infections, 2017-2032 (USD Million)
TABLE 190. GCC Antinematode Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 191. GCC Antinematode Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 192. European Union Antinematode Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 193. European Union Antinematode Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 194. European Union Antinematode Drugs Market Size, by Avermectins, 2017-2032 (USD Million)
TABLE 195. European Union Antinematode Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 196. European Union Antinematode Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 197. European Union Antinematode Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 198. European Union Antinematode Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 199. European Union Antinematode Drugs Market Size, by Filariasis, 2017-2032 (USD Million)
TABLE 200. European Union Antinematode Drugs Market Size, by Gastrointestinal Nematode Infections, 2017-2032 (USD Million)
TABLE 201. European Union Antinematode Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 202. European Union Antinematode Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 203. BRICS Antinematode Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 204. BRICS Antinematode Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 205. BRICS Antinematode Drugs Market Size, by Avermectins, 2017-2032 (USD Million)
TABLE 206. BRICS Antinematode Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 207. BRICS Antinematode Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 208. BRICS Antinematode Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 209. BRICS Antinematode Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 210. BRICS Antinematode Drugs Market Size, by Filariasis, 2017-2032 (USD Million)
TABLE 211. BRICS Antinematode Drugs Market Size, by Gastrointestinal Nematode Infections, 2017-2032 (USD Million)
TABLE 212. BRICS Antinematode Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 213. BRICS Antinematode Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 214. G7 Antinematode Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 215. G7 Antinematode Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 216. G7 Antinematode Drugs Market Size, by Avermectins, 2017-2032 (USD Million)
TABLE 217. G7 Antinematode Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 218. G7 Antinematode Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 219. G7 Antinematode Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 220. G7 Antinematode Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 221. G7 Antinematode Drugs Market Size, by Filariasis, 2017-2032 (USD Million)
TABLE 222. G7 Antinematode Drugs Market Size, by Gastrointestinal Nematode Infections, 2017-2032 (USD Million)
TABLE 223. G7 Antinematode Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 224. G7 Antinematode Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 225. NATO Antinematode Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 226. NATO Antinematode Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 227. NATO Antinematode Drugs Market Size, by Avermectins, 2017-2032 (USD Million)
TABLE 228. NATO Antinematode Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 229. NATO Antinematode Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 230. NATO Antinematode Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 231. NATO Antinematode Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 232. NATO Antinematode Drugs Market Size, by Filariasis, 2017-2032 (USD Million)
TABLE 233. NATO Antinematode Drugs Market Size, by Gastrointestinal Nematode Infections, 2017-2032 (USD Million)
TABLE 234. NATO Antinematode Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 235. NATO Antinematode Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 236. Global Antinematode Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 237. United States Antinematode Drugs Market Size, 2017-2032 (USD Million)
TABLE 238. United States Antinematode Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 239. United States Antinematode Drugs Market Size, by Avermectins, 2017-2032 (USD Million)
TABLE 240. United States Antinematode Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 241. United States Antinematode Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 242. United States Antinematode Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 243. United States Antinematode Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 244. United States Antinematode Drugs Market Size, by Filariasis, 2017-2032 (USD Million)
TABLE 245. United States Antinematode Drugs Market Size, by Gastrointestinal Nematode Infections, 2017-2032 (USD Million)
TABLE 246. United States Antinematode Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 247. United States Antinematode Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 248. Canada Antinematode Drugs Market Size, 2017-2032 (USD Million)
TABLE 249. Canada Antinematode Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 250. Canada Antinematode Drugs Market Size, by Avermectins, 2017-2032 (USD Million)
TABLE 251. Canada Antinematode Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 252. Canada Antinematode Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 253. Canada Antinematode Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 254. Canada Antinematode Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 255. Canada Antinematode Drugs Market Size, by Filariasis, 2017-2032 (USD Million)
TABLE 256. Canada Antinematode Drugs Market Size, by Gastrointestinal Nematode Infections, 2017-2032 (USD Million)
TABLE 257. Canada Antinematode Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 258. Canada Antinematode Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 259. Mexico Antinematode Drugs Market Size, 2017-2032 (USD Million)
TABLE 260. Mexico Antinematode Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 261. Mexico Antinematode Drugs Market Size, by Avermectins, 2017-2032 (USD Million)
TABLE 262. Mexico Antinematode Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 263. Mexico Antinematode Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 264. Mexico Antinematode Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 265. Mexico Antinematode Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 266. Mexico Antinematode Drugs Market Size, by Filariasis, 2017-2032 (USD Million)
TABLE 267. Mexico Antinematode Drugs Market Size, by Gastrointestinal Nematode Infections, 2017-2032 (USD Million)
TABLE 268. Mexico Antinematode Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 269. Mexico Antinematode Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 270. Brazil Antinematode Drugs Market Size, 2017-2032 (USD Million)
TABLE 271. Brazil Antinematode Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 272. Brazil Antinematode Drugs Market Size, by Avermectins, 2017-2032 (USD Million)
TABLE 273. Brazil Antinematode Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 274. Brazil Antinematode Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 275. Brazil Antinematode Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 276. Brazil Antinematode Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 277. Brazil Antinematode Drugs Market Size, by Filariasis, 2017-2032 (USD Million)
TABLE 278. Brazil Antinematode Drugs Market Size, by Gastrointestinal Nematode Infections, 2017-2032 (USD Million)
TABLE 279. Brazil Antinematode Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 280. Brazil Antinematode Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 281. United Kingdom Antinematode Drugs Market Size, 2017-2032 (USD Million)
TABLE 282. United Kingdom Antinematode Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 283. United Kingdom Antinematode Drugs Market Size, by Avermectins, 2017-2032 (USD Million)
TABLE 284. United Kingdom Antinematode Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 285. United Kingdom Antinematode Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 286. United Kingdom Antinematode Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 287. United Kingdom Antinematode Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 288. United Kingdom Antinematode Drugs Market Size, by Filariasis, 2017-2032 (USD Million)
TABLE 289. United Kingdom Antinematode Drugs Market Size, by Gastrointestinal Nematode Infections, 2017-2032 (USD Million)
TABLE 290. United Kingdom Antinematode Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 291. United Kingdom Antinematode Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 292. Germany Antinematode Drugs Market Size, 2017-2032 (USD Million)
TABLE 293. Germany Antinematode Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 294. Germany Antinematode Drugs Market Size, by Avermectins, 2017-2032 (USD Million)
TABLE 295. Germany Antinematode Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 296. Germany Antinematode Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 297. Germany Antinematode Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 298. Germany Antinematode Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 299. Germany Antinematode Drugs Market Size, by Filariasis, 2017-2032 (USD Million)
TABLE 300. Germany Antinematode Drugs Market Size, by Gastrointestinal Nematode Infections, 2017-2032 (USD Million)
TABLE 301. Germany Antinematode Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 302. Germany Antinematode Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 303. France Antinematode Drugs Market Size, 2017-2032 (USD Million)
TABLE 304. France Antinematode Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 305. France Antinematode Drugs Market Size, by Avermectins, 2017-2032 (USD Million)
TABLE 306. France Antinematode Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 307. France Antinematode Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 308. France Antinematode Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 309. France Antinematode Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 310. France Antinematode Drugs Market Size, by Filariasis, 2017-2032 (USD Million)
TABLE 311. France Antinematode Drugs Market Size, by Gastrointestinal Nematode Infections, 2017-2032 (USD Million)
TABLE 312. France Antinematode Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 313. France Antinematode Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 314. Russia Antinematode Drugs Market Size, 2017-2032 (USD Million)
TABLE 315. Russia Antinematode Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 316. Russia Antinematode Drugs Market Size, by Avermectins, 2017-2032 (USD Million)
TABLE 317. Russia Antinematode Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 318. Russia Antinematode Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 319. Russia Antinematode Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 320. Russia Antinematode Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 321. Russia Antinematode Drugs Market Size, by Filariasis, 2017-2032 (USD Million)
TABLE 322. Russia Antinematode Drugs Market Size, by Gastrointestinal Nematode Infections, 2017-2032 (USD Million)
TABLE 323. Russia Antinematode Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 324. Russia Antinematode Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 325. Italy Antinematode Drugs Market Size, 2017-2032 (USD Million)
TABLE 326. Italy Antinematode Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 327. Italy Antinematode Drugs Market Size, by Avermectins, 2017-2032 (USD Million)
TABLE 328. Italy Antinematode Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 329. Italy Antinematode Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 330. Italy Antinematode Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 331. Italy Antinematode Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 332. Italy Antinematode Drugs Market Size, by Filariasis, 2017-2032 (USD Million)
TABLE 333. Italy Antinematode Drugs Market Size, by Gastrointestinal Nematode Infections, 2017-2032 (USD Million)
TABLE 334. Italy Antinematode Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 335. Italy Antinematode Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 336. Spain Antinematode Drugs Market Size, 2017-2032 (USD Million)
TABLE 337. Spain Antinematode Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 338. Spain Antinematode Drugs Market Size, by Avermectins, 2017-2032 (USD Million)
TABLE 339. Spain Antinematode Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 340. Spain Antinematode Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 341. Spain Antinematode Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 342. Spain Antinematode Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 343. Spain Antinematode Drugs Market Size, by Filariasis, 2017-2032 (USD Million)
TABLE 344. Spain Antinematode Drugs Market Size, by Gastrointestinal Nematode Infections, 2017-2032 (USD Million)
TABLE 345. Spain Antinematode Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 346. Spain Antinematode Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 347. China Antinematode Drugs Market Size, 2017-2032 (USD Million)
TABLE 348. China Antinematode Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 349. China Antinematode Drugs Market Size, by Avermectins, 2017-2032 (USD Million)
TABLE 350. China Antinematode Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 351. China Antinematode Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 352. China Antinematode Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 353. China Antinematode Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 354. China Antinematode Drugs Market Size, by Filariasis, 2017-2032 (USD Million)
TABLE 355. China Antinematode Drugs Market Size, by Gastrointestinal Nematode Infections, 2017-2032 (USD Million)
TABLE 356. China Antinematode Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 357. China Antinematode Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 358. India Antinematode Drugs Market Size, 2017-2032 (USD Million)
TABLE 359. India Antinematode Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 360. India Antinematode Drugs Market Size, by Avermectins, 2017-2032 (USD Million)
TABLE 361. India Antinematode Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE

Companies Mentioned

  • Anhui Shengying Pharmaceutical Co., Ltd.
  • Bayer AG
  • Beijing Taiyang Pharmaceutical Co., Ltd.
  • Boehringer Ingelheim International GmbH
  • Elanco Animal Health Incorporated
  • Geevet Remedies Pvt Ltd
  • GlaxoSmithKline plc
  • Guilin Nanyao Pharmaceutical Co., Ltd.
  • Hubei Ruihua Pharmaceutical Co., Ltd.
  • Imperia Lifesciences Pvt Ltd
  • Jiaozuo Furuitang Pharmaceutical Co., Ltd.
  • Jinhe Biotechnology Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Shaanxi Hanwang Pharmaceutical Co., Ltd.
  • Shandong Luxi Veterinary Pharmaceutical Co., Ltd.
  • Shanghai SPH Xinyi Pharmaceutical Co., Ltd.
  • Shanghai Tengrui Pharmaceutical Co., Ltd.
  • Shaoxing Minsheng Pharmaceutical Co., Ltd.
  • Shijiazhuang Shimu Pharmaceutical Co., Ltd.
  • Sichuan Hengtong Animal Protection Biotechnology Co., Ltd.
  • Sichuan Tiande Pharmaceutical Co., Ltd.
  • Zhejiang Anbet Pharmaceutical Co., Ltd.
  • Zhengzhou Yuxiang Agricultural Science and Technology Co., Ltd.
  • Zoetis Inc.

Related Topics

Related Reports

Anti-helminthic Drugs Market - Global Forecast 2026-2032 - Product Image

Anti-helminthic Drugs Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Gout Medications Market - Global Forecast 2026-2032 - Product Image

Gout Medications Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From
Vitamin D Therapy - Global Strategic Business Report - Product Image

Vitamin D Therapy - Global Strategic Business Report

  • Report
  • 222 Pages
  • Global
From
Prescription Drugs - Global Strategic Business Report - Product Image

Prescription Drugs - Global Strategic Business Report

  • Report
  • 362 Pages
  • Global
From
GLP-1 Therapies - Market Insights, Competitive Landscape, and Market Forecast - 2034 - Product Image

GLP-1 Therapies - Market Insights, Competitive Landscape, and Market Forecast - 2034

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.